What We DONT Know Yet Heres what we DONT have: We have no controlled trials of women deliberately taking GLP-1s during pregnancy (and well never have theseit would be unethical)
Some GLP-1 receptor agonists, like Tirzepatide, have been shown to reduce the risk of major cardiovascular events (e.g., heart attack, stroke) in people with Type 2 diabetes and existing heart disease
eligible Medicare patients can access FDA-approved GLP-1 medications for $50/month through the CMS Medicare GLP-1 Bridge Program - a different pathway worth evaluating before enrolling in a cash-pay compounded program FDA adverse event data (as of May 21, 2026): FDA had received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide combined - a safety signal not specific to Omzo but material context for any compounded GLP-1 enrollment decision
Originally identified for its role in blood sugar regulation, GLP-1 has gained tremendous attention for its effects on appetite control, with pharmaceutical GLP-1 receptor agonists showing remarkable weight loss results in clinical settings
Do GLP-1 medications cause muscle loss